Kuva Labs Acquires Lisata Therapeutics

Selvita S.A. Acquires PozLab

May 7, 2024

Pharmaceuticals

Selvita S.A. has completed the acquisition of 100% of the shares in PozLab, a Poznan-based CDMO providing drug product development, analytical and microbiological testing, and small pilot plant manufacturing under GMP. The deal expands Selvita's service offering beyond preclinical research into small-molecule drug manufacturing for early-stage clinical trials and strengthens its position in the pharmaceutical research value chain.

Kintara Therapeutics Proposed Merger with TuHURA Biosciences

October 14, 2024

Healthcare Services

Kintara Therapeutics entered into a definitive merger agreement with TuHURA Biosciences, under which Kayak Mergeco will merge with and into TuHURA, with TuHURA surviving and becoming Kintara’s direct, wholly-owned subsidiary. The transaction is expected to close October 18, 2024, subject to regulatory approval and remaining closing conditions. Kintara will issue contingent value rights (CVRs) to its stockholders prior to closing tied to milestone achievement.

TuHURA Biosciences Completes Acquisition of Kineta

June 30, 2025

Healthcare Services

TuHURA Biosciences has completed its acquisition of Kineta, adding Kineta’s VISTA-inhibiting monoclonal antibody (renamed TBS-2025) to TuHURA’s late-stage immuno-oncology pipeline. The deal is expected to support TuHURA’s Phase 2 plans for TBS-2025 (in combination strategies) and unlock additional PIPE financing tranches tied to the merger completion.

Somatus Acquires Strategic Assets from Lumiata

April 28, 2022

Healthcare Services

Somatus has acquired strategic assets from Lumiata to integrate Lumiata's healthcare AI and predictive analytics into Somatus' RenalIQ platform, improving early identification of people with chronic kidney disease and prediction of disease progression. The deal brings Lumiata talent (including Jessica McCarthy) into Somatus and aims to strengthen care delivery, reduce costs for provider and health-plan partners, and address health inequities.

Bristol Myers Squibb to Acquire Mirati Therapeutics in $4.8B Cash-and-CVR Deal

October 13, 2023

Pharmaceuticals

Bristol Myers Squibb has entered into a definitive merger agreement to acquire Mirati Therapeutics for $58 per share in cash, valuing the transaction at $4.8 billion in equity value. The deal also includes a non-tradeable contingent value right (CVR) that could provide up to an additional $1 billion of value tied to regulatory acceptance of an NDA for Mirati’s MRTX1719.

Lantheus Holdings Acquires Cerveau Technologies

February 6, 2023

Pharmaceuticals

Lantheus Holdings, Inc. acquired Knoxville-based Cerveau Technologies, Inc., gaining MK-6240, a clinical-stage F-18 PET imaging agent that targets Tau tangles in Alzheimer's disease. The stock purchase includes upfront and potential milestone payments plus royalty obligations and will expand Lantheus' radiopharmaceutical diagnostic imaging pipeline and research collaborations.